AHPA Comments On Vinpocetine: Health And Wellness Industry News Roundup

AHPA argues FDA erred in vinpocetine proposal; and MusclePharm CEO bails out firm again.

FDA's proposal to remove vinpocetine from use in dietary supplements did not thoroughly consider the ingredient's history of use and ignores language in the regulation the agency partly bases its decision on, the American Herbal Products Association says.

While FDA stated its Sept. 7 notice of proposed rulemaking that its database and literature searches "did not identify any food use of vinpocetine, such use was possibly overlooked," AHPA President Michael McGuffin and General Counsel Tony Young state in comments submitted to FDA Nov. 7

More from United States

More from North America